CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)

CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)

Abstract Background Cisplatin (DDP) is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and long-term DDP stimulation increased resistance of NSCLC cells to this drug by enriching cancer stem cells (CSCs), which contributed to recurrence and worse prognosis of NSCLC, but...

Full description

Bibliographic Details
Main Authors: Yongsheng Zhao, Renyan Zheng, Jian Chen, Dong Ning
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Cancer Cell International
Subjects:
Cisplatin
Non-small cell lung cancer
Cancer stem cells
Chemoresistance
Online Access:http://link.springer.com/article/10.1186/s12935-020-01390-w

Internet

http://link.springer.com/article/10.1186/s12935-020-01390-w

Similar Items